227 related articles for article (PubMed ID: 38365611)
21. Comprehensive analysis for the immune related biomarkers of platinum-based chemotherapy in ovarian cancer.
Liu J; Liu Y; Yang C; Liu J; Hao J
Transl Oncol; 2023 Nov; 37():101762. PubMed ID: 37619523
[TBL] [Abstract][Full Text] [Related]
22. Prognostic values and prospective pathway signaling of MicroRNA-182 in ovarian cancer: a study based on gene expression omnibus (GEO) and bioinformatics analysis.
Li Y; Li L
J Ovarian Res; 2019 Nov; 12(1):106. PubMed ID: 31703725
[TBL] [Abstract][Full Text] [Related]
23. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer.
Cai X; Lin J; Liu L; Zheng J; Liu Q; Ji L; Sun Y
BMC Cancer; 2024 Apr; 24(1):515. PubMed ID: 38654239
[TBL] [Abstract][Full Text] [Related]
24. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
25. LRRC superfamily expression in stromal cells predicts the clinical prognosis and platinum resistance of ovarian cancer.
Zhu X; You S; Du X; Song K; Lv T; Zhao H; Yao Q
BMC Med Genomics; 2023 Jan; 16(1):10. PubMed ID: 36653841
[TBL] [Abstract][Full Text] [Related]
26. Identification of STEAP3-based molecular subtype and risk model in ovarian cancer.
Zhao Z; Sun C; Hou J; Yu P; Wei Y; Bai R; Yang P
J Ovarian Res; 2023 Jun; 16(1):126. PubMed ID: 37386521
[TBL] [Abstract][Full Text] [Related]
27. Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status.
Li Y; Nie Y; Guo H; Guo H; Ha C; Li Y
Front Oncol; 2022; 12():847085. PubMed ID: 35372049
[TBL] [Abstract][Full Text] [Related]
28. NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer.
Konrad SM; Schwamborn K; Krüger A; Honert K; Schmitt M; Hellmann D; Schmalfeldt B; Meindl A; Kiechle M; Quante AS; Brambs C; Grill S; Ramser J
Biomark Med; 2022 Oct; 16(14):1029-1041. PubMed ID: 36444691
[No Abstract] [Full Text] [Related]
29. Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.
Shen J; Yu S; Sun X; Yin M; Fei J; Zhou J
J Ovarian Res; 2019 Nov; 12(1):110. PubMed ID: 31729978
[TBL] [Abstract][Full Text] [Related]
30. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
31. Identification of latent biomarkers in connection with progression and prognosis in oral cancer by comprehensive bioinformatics analysis.
Reyimu A; Chen Y; Song X; Zhou W; Dai J; Jiang F
World J Surg Oncol; 2021 Aug; 19(1):240. PubMed ID: 34384424
[TBL] [Abstract][Full Text] [Related]
32. High expression of CETN2 is associated with platinum resistance and poor prognosis in epithelial ovarian cancer.
Qiu PY; Deng XH; Li L
Clin Transl Oncol; 2023 May; 25(5):1340-1352. PubMed ID: 36527574
[TBL] [Abstract][Full Text] [Related]
33. Prospective pathway signaling and prognostic values of MicroRNA-9 in ovarian cancer based on gene expression omnibus (GEO): a bioinformatics analysis.
Zuo L; Li X; Tan Y; Zhu H; Xiao M
J Ovarian Res; 2021 Feb; 14(1):29. PubMed ID: 33563317
[TBL] [Abstract][Full Text] [Related]
34. CircITGB6 promotes ovarian cancer cisplatin resistance by resetting tumor-associated macrophage polarization toward the M2 phenotype.
Li H; Luo F; Jiang X; Zhang W; Xiang T; Pan Q; Cai L; Zhao J; Weng D; Li Y; Dai Y; Sun F; Yang C; Huang Y; Yang J; Tang Y; Han Y; He M; Zhang Y; Song L; Xia JC
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35277458
[TBL] [Abstract][Full Text] [Related]
35. New markers for human ovarian cancer that link platinum resistance to the cancer stem cell phenotype and define new therapeutic combinations and diagnostic tools.
Muñoz-Galván S; Felipe-Abrio B; García-Carrasco M; Domínguez-Piñol J; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sánchez A; Navas LE; Otero-Albiol D; Marin JJ; Jiménez-García MP; García-Heredia JM; Quiroga AG; Estevez-Garcia P; Carnero A
J Exp Clin Cancer Res; 2019 Jun; 38(1):234. PubMed ID: 31159852
[TBL] [Abstract][Full Text] [Related]
36. Insulin-like growth factor 2 mRNA-binding protein 2 is a therapeutic target in ovarian cancer.
Yuan J; Li X; Wang F; Liu H; Guan W; Xu G
Exp Biol Med (Maywood); 2023 Dec; 248(23):2198-2209. PubMed ID: 38084732
[TBL] [Abstract][Full Text] [Related]
37. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
38. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of LINC01508 contributes to cisplatin resistance in ovarian cancer via the regulation of the Hippo-YAP pathway.
Xiao L; Shi XY; Li ZL; Li M; Zhang MM; Yan SJ; Wei ZL
J Gynecol Oncol; 2021 Sep; 32(5):e77. PubMed ID: 34132072
[TBL] [Abstract][Full Text] [Related]
40. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
